Logo image of ALEMS.BR

EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR) Stock Fundamental Analysis

EBR:ALEMS - Euronext Brussels - BE0974497290 - Common Stock - Currency: EUR

6.68  +0.48 (+7.74%)

Fundamental Rating

2

Overall ALEMS gets a fundamental rating of 2 out of 10. We evaluated ALEMS against 72 industry peers in the Biotechnology industry. Both the profitability and financial health of ALEMS have multiple concerns. ALEMS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ALEMS had negative earnings in the past year.
In the past year ALEMS had a positive cash flow from operations.
In the past 5 years ALEMS always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: ALEMS reported negative operating cash flow in multiple years.
ALEMS.BR Yearly Net Income VS EBIT VS OCF VS FCFALEMS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

ALEMS has a Return On Assets of -2.37%. This is in the better half of the industry: ALEMS outperforms 71.88% of its industry peers.
ALEMS has a better Return On Equity (-10.55%) than 67.19% of its industry peers.
Industry RankSector Rank
ROA -2.37%
ROE -10.55%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALEMS.BR Yearly ROA, ROE, ROICALEMS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600 -800

1.3 Margins

ALEMS has a Gross Margin (17.08%) which is in line with its industry peers.
ALEMS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALEMS.BR Yearly Profit, Operating, Gross MarginsALEMS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10

More info and screens

3

2. Health

2.1 Basic Checks

ALEMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ALEMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALEMS.BR Yearly Shares OutstandingALEMS.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 500M 1B
ALEMS.BR Yearly Total Debt VS Total AssetsALEMS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

ALEMS has an Altman-Z score of 168.43. This indicates that ALEMS is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 168.43, ALEMS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
A Debt/Equity ratio of 1.41 is on the high side and indicates that ALEMS has dependencies on debt financing.
With a Debt to Equity ratio value of 1.41, ALEMS is not doing good in the industry: 68.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.41
Debt/FCF N/A
Altman-Z 168.43
ROIC/WACCN/A
WACC7.44%
ALEMS.BR Yearly LT Debt VS Equity VS FCFALEMS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M -10M

2.3 Liquidity

ALEMS has a Current Ratio of 1.46. This is a normal value and indicates that ALEMS is financially healthy and should not expect problems in meeting its short term obligations.
ALEMS's Current ratio of 1.46 is on the low side compared to the rest of the industry. ALEMS is outperformed by 67.19% of its industry peers.
ALEMS has a Quick Ratio of 1.46. This is a bad value and indicates that ALEMS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.85, ALEMS is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.46
Quick Ratio 0.85
ALEMS.BR Yearly Current Assets VS Current LiabilitesALEMS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

ALEMS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.57%.
ALEMS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.86%.
EPS 1Y (TTM)-28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.02%
Revenue 1Y (TTM)9.86%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5.07%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALEMS.BR Yearly Revenue VS EstimatesALEMS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ALEMS.BR Yearly EPS VS EstimatesALEMS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
ALEMS.BR Price Earnings VS Forward Price EarningsALEMS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ALEMS is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7260.13
ALEMS.BR Per share dataALEMS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.01 0.01 0.02 0.02 0.03

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALEMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUROPEAN MEDICAL SOLUTIONS S

EBR:ALEMS (2/4/2025, 7:00:00 PM)

6.68

+0.48 (+7.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-16 2025-01-16
Earnings (Next)N/A N/A
Inst Owners0.02%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap9.95B
Analysts34.29
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 239.08
P/FCF N/A
P/OCF 15997.74
P/B 979.39
P/tB 6910.14
EV/EBITDA 7260.13
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFY0.01%
SpS0.03
BVpS0.01
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.37%
ROE -10.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 17.08%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity 1.41
Debt/FCF N/A
Debt/EBITDA 10.47
Cap/Depr 160.58%
Cap/Sales 7.5%
Interest Coverage N/A
Cash Conversion 45.34%
Profit Quality N/A
Current Ratio 1.46
Quick Ratio 0.85
Altman-Z 168.43
F-Score4
WACC7.44%
ROIC/WACCN/A
Cap/Depr(3y)88.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)5.97%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.02%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.86%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y137.36%
OCF growth 3YN/A
OCF growth 5YN/A